FP-045 is under clinical development by Foresee Pharmaceuticals and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect FP-045’s likelihood of approval (LoA) and phase transition for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) took place on 10 Oct 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their FP-045 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

FP-045 overview

FP-045 is under development for the treatment of radiation-induced dermatitis, peripheral arterial disease and fanconi anemia. The therapeutic candidate is a small molecule. It is administered through oral route. It acts by targeting aldehyde dehydrogenase-2 (ALDH2). It was also under development for the treatment of acute and chronic aldehyde metabolism disorders, inflammatory pain, myocardial ischemia and post-myocardial infarction (post-MI).

Foresee Pharmaceuticals overview

Foresee Pharmaceuticals (FP) is a clinical-stage pharmaceutical company. It focuses on developing drugs for unmet medical needs. The company’s product portfolio comprises FP-001, for prostate cancer, FP-002, for acromegaly and carcinoid tumors, FP-025, for asthma and chronic obstructive pulmonary disease, FP-020, for Alport syndrome and FP-008, for diabetic retinopathy. It harnesses the stabilized injectable formulation (SIF) platform technology to develop controlled release drug delivery systems for peptides, small molecules and proteins. The company works in collaboration with ScinoPharm and Pierre Fabre to research and develop its product portfolio. It has operational presence in Taiwan and the US. FP is headquartered in Taipei, Taiwan.

Quick View FP-045 LOA Data

Report Segments
  • Innovator
Drug Name
  • FP-045
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Hematological Disorders
  • Toxicology
Key Developers
  • Sponsor Company: Foresee Pharmaceuticals
Highest Development Stage
  • Phase I

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.